Patrick Phillips, PhD, MS, MA
Associate Professor
Medicine
School of Medicine

The objective of my research is to design, implement, and optimize clinical trials for new treatments for tuberculosis in order to deliver safer and more efficacious regimens for patients. I lead the Trial Design and Statistics core of the PanACEA consortium evaluating novel regimens for the treatment of TB, am consultant statistician for the US CDC-funded TB Trials Consortium (TBTC), and a member of the ACTG TB Transformative Science Steering Group. I have worked on late-phase clinical trials in tuberculosis for more than fifteen years, most recently as trial statistician in the STREAM Stage 1 and the TBTC/ACTG S31/A5349 phase III trials and vice-chair of ACTG A5414 SPECTR-TB. Ongoing methodological areas of interest include the evaluation and use of surrogate endpoints, the conduct and analysis of non-inferiority trials and trial design with a focus on adaptive designs. I am an associate editor for the journal BMC Trials.

• Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial.
  Trials 2024 Weir IR, Dufault SM, Phillips PPJ
• Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.
  PLoS medicine 2024 Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, Kunihira Tinka L, Nakimuli J, Ritar Kasidi J, Bishop O, Nakasendwa S, Baik Y, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, …
• New manual qPCR assay validated on tongue swabs collected and processed in Uganda shows sensitivity that rivals sputum-based molecular TB diagnostics.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024 Steadman A, Andama A, Ball A, Mukwatamundu J, Khimani K, Mochizuki T, Asege L, Bukirwa A, Kato JB, Katumba D, Kisakye E, Mangeni W, Mwebe S, Nakaye M, Nassuna I, Nyawere J, Nakaweesa A, Cook C, …
• Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South Africa.
  The Lancet. Global health 2024 Gupta-Wright A, Ha H, Abdulgadar S, Crowder R, Emmanuel J, Mukwatamundu J, Marcelo D, Phillips PPJ, Christopher DJ, Nhung NV, Theron G, Yu C, Nahid P, Cattamanchi A, Worodria W, Denkinger CM, R2D2 TB …
• Cost-effectiveness of Low-complexity Screening Tests in Community-based Case-finding for Tuberculosis.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024 Brümmer LE, Thompson RR, Malhotra A, Shrestha S, Kendall EA, Andrews JR, Phillips P, Nahid P, Cattamanchi A, Marx FM, Denkinger CM, Dowdy DW
• Tuberculosis treatment monitoring tests during routine practice: study design guidance.
  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2024 MacLean EL, Zimmer AJ, den Boon S, Gupta-Wright A, Cirillo DM, Cobelens F, Gillespie SH, Nahid P, Phillips PP, Ruhwald M, Denkinger CM
• A flexible multi-metric Bayesian framework for decision-making in Phase II multi-arm multi-stage studies.
  Statistics in medicine 2023 Dufault SM, Crook AM, Rolfe K, Phillips PPJ
• Standards for clinical trials for treating TB.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2023 du Cros P, Greig J, Alffenaar JC, Cross GB, Cousins C, Berry C, Khan U, Phillips PPJ, Velásquez GE, Furin J, Spigelman M, Denholm JT, Thi SS, Tiberi S, Huang GKL, Marks GB, Turkova A, Guglielmetti L, …
• Estimands for clinical endpoints in Tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial.
  Research square 2023 Weir IR, Dufault SM, Phillips PP
• Treatment-shortening regimens for tuberculosis: updates and future priorities.
  Breathe (Sheffield, England) 2023 Saluzzo F, Adepoju VA, Duarte R, Lange C, Phillips PPJ
• Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
  Antimicrobial agents and chemotherapy 2023 Stemkens R, Jager Vd, Dawson R, Diacon AH, Narunsky K, Padayachee SD, Boeree MJ, van Beek SW, Colbers A, Coenen MJH, Svensson EM, Fuhr U, Phillips PPJ, Te Brake LHM, Aarnoutse RE, PanACEA consortium
• A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis.
  Trials 2023 Dierig A, Hoelscher M, Schultz S, Hoffmann L, Jarchow-MacDonald A, Svensson EM, Te Brake L, Aarnoutse R, Boeree M, McHugh TD, Wildner LM, Gong X, Phillips P, Minja LT, Ntinginya N, Mpagama S, Liyoyo A…
• Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study.
  Clinical trials (London, England) 2023 Rehal S, Cro S, Phillips PP, Fielding K, Carpenter JR
• A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials.
  American journal of respiratory and critical care medicine 2023 Kurbatova EV, Phillips PPJ, Dorman SE, Sizemore EE, Bryant KE, Purfield AE, Ricaldi J, Brown NE, Johnson JL, Wallis CL, Akol JP, Ocheretina O, Van Hung N, Mayanja-Kizza H, Lourens M, Dawson R, Nhung …
• Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania.
  Pilot and feasibility studies 2023 Mpagama SG, Mvungi HC, Mbelele PM, Semvua HH, Liyoyo AA, de Guex KP, Sloan D, Kibiki GS, Boeree M, Phillips PPJ, Heysell SK
• Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects.
  International journal of antimicrobial agents 2023 Koele SE, Phillips PPJ, Upton CM, van Ingen J, Simonsson USH, Diacon AH, Aarnoutse RE, Svensson EM
• Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Pettit AC, Phillips PPJ, Kurbatova E, Vernon A, Nahid P, Dawson R, Dooley KE, Sanne I, Waja Z, Mohapi L, Podany AT, Samaneka W, Savic RM, Johnson JL, Muzanyi G, Lalloo UG, Bryant K, Sizemore E, Scott …
• Tuberculosis Molecular Bacterial Load Assay Reveals Early Delayed Bacterial Killing in Patients With Relapse.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Ntinginya NE, Bakuli A, Mapamba D, Sabiiti W, Kibiki G, Minja LT, Kuchaka D, Reither K, Phillips PPJ, Boeree MJ, Gillespie SH, Hoelscher M, Heinrich N, Pan African Consortium for the Evaluation of …
• Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3 months weekly isoniazid-rifapentine.
  AIDS (London, England) 2023 Chaisson LH, Semitala FC, Nangobi F, Steinmetz S, Marquez C, Armstrong DT, Opira B, Kamya MR, Phillips PPJ, Dowdy DW, Yoon C
• To Err Is Human, to Forgive Is Pharmacodynamic.
  American journal of respiratory and critical care medicine 2023 Phillips PPJ, Stout JE
• A comparison of clinical development pathways to advance tuberculosis regimen development.
  BMC infectious diseases 2022 Chang V, Phillips PPJ, Imperial MZ, Nahid P, Savic RM
• Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Podany AT, Pham M, Sizemore E, Martinson N, Samaneka W, Mohapi L, Badal-Faesen S, Dawson R, Johnson JL, Mayanja H, Lalloo U, Whitworth WC, Pettit A, Campbell K, Phillips PPJ, Bryant K, Scott N, Vernon…
• Factors associated with screening failure and study withdrawal in multidrug-resistant TB.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2022 Schwalb A, Cachay R, Wright A, Phillips PPJ, Kaur P, Diacon AH, Ugarte-Gil C, Mitnick CD, Sterling TR, Gotuzzo E, Horsburgh CR
• Rethinking intercurrent events in defining estimands for tuberculosis trials.
  Clinical trials (London, England) 2022 Pham TM, Tweed CD, Carpenter JR, Kahan BC, Nunn AJ, Crook AM, Esmail H, Goodall R, Phillips PP, White IR
• Tuberculosis screening improves preventive therapy uptake (TB SCRIPT) trial among people living with HIV in Uganda: a study protocol of an individual randomized controlled trial.
  Trials 2022 Semitala FC, Chaisson LH, Dowdy DW, Armstrong DT, Opira B, Aman K, Kamya M, Phillips PPJ, Yoon C
• Four-Month Rifapentine Regimens for Tuberculosis. Reply.
  The New England journal of medicine 2022 Phillips PPJ, Kurbatova EV, Dorman SE
• Clinical Impact of the Line Probe Assay and Xpert® MTB/RIF Assay in the Presumptive Diagnosis of Drug-Resistant Tuberculosis in Brazil: A Pragmatic Clinical Trial.
  Revista da Sociedade Brasileira de Medicina Tropical 2022 Kritski A, Oliveira MM, Almeida IN, Ramalho D, Andrade MKN, Carvalho M, Miranda PFC, Dalcolmo MP, Braga JU, Brígido T, Mesquita E, Dias C, Gambirasio A, Souza Filho JB, Detjen A, Phillips PPJ, Langley…
• MOVER approximated CV: A tool for quantifying precision in ratiometric droplet digital PCR assays.
  Journal of pharmaceutical and biomedical analysis 2022 Dide-Agossou C, Rossmassler K, Reid J, Purohit J, Savic RM, Nahid P, Phillips PPJ, Moore CM, Walter ND
• Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
  PLoS medicine 2021 Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka…
• Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials.
  American journal of respiratory and critical care medicine 2021 Imperial MZ, Phillips PPJ, Nahid P, Savic RM
• Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
  Trials 2021 Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, Chang E, Cloez S, Coit JM, Cox V, de Jong BC, Delifer C, Do JM, Tozzi DDS, Ducher V, Ferlazzo G, Gouillou M, Khan A, Khan U, …
• A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials.
  Trials 2021 Hills NK, Lyimo J, Nahid P, Savic RM, Lienhardt C, Phillips PPJ
• Optimising pyrazinamide for the treatment of tuberculosis.
  The European respiratory journal 2021 Zhang N, Savic RM, Boeree MJ, Peloquin CA, Weiner M, Heinrich N, Bliven-Sizemore E, Phillips PPJ, Hoelscher M, Whitworth W, Morlock G, Posey J, Stout JE, Mac Kenzie W, Aarnoutse R, Dooley KE, …
• Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg-1 rifampicin.
  The European respiratory journal 2021 Te Brake LHM, de Jager V, Narunsky K, Vanker N, Svensson EM, Phillips PPJ, Gillespie SH, Heinrich N, Hoelscher M, Dawson R, Diacon AH, Aarnoutse RE, Boeree MJ, PanACEA Consortium
• Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
  The New England journal of medicine 2021 Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH,…
• Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania.
  Journal of clinical microbiology 2021 Mbelele PM, Mpolya EA, Sauli E, Mtafya B, Ntinginya NE, Addo KK, Kreppel K, Mfinanga S, Phillips PPJ, Gillespie SH, Heysell SK, Sabiiti W, Mpagama SG
• The use of molecular genetic diagnostic tests to improve MDR TB treatment outcomes in Arkhangelsk Region
  Tuberculosis and Lung Diseases 2021 Eliseev, P. I.; Maryandyshev, A. O.; Detjen, A.; Dacombe, R.; Squire, S. B.; Phillips, P.
• Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial.
  BMC medicine 2020 Phillips PPJ, Van Deun A, Ahmed S, Goodall RL, Meredith SK, Conradie F, Chiang CY, Rusen ID, Nunn AJ
• Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda.
  Implementation science : IS 2020 Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba …
• Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection.
  American journal of respiratory and critical care medicine 2020 Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ
• Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay.
  Thorax 2020 Sabiiti W, Azam K, Farmer ECW, Kuchaka D, Mtafya B, Bowness R, Oravcova K, Honeyborne I, Evangelopoulos D, McHugh TD, Khosa C, Rachow A, Heinrich N, Kampira E, Davies G, Bhatt N, Ntinginya EN, Viegas …
• Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling.
  American journal of respiratory and critical care medicine 2020 Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ
• Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial.
  Bulletin of the World Health Organization 2020 Madan JJ, Rosu L, Tefera MG, van Rensburg C, Evans D, Langley I, Tomeny EM, Nunn A, Phillips PP, Rusen ID, Squire SB, STREAM study health economic evaluation collaborators
• High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
  Contemporary clinical trials 2020 Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, …
• Q fever-the superstition of avoiding the word "quiet" as a coping mechanism: randomised controlled non-inferiority trial.
  BMJ (Clinical research ed.) 2019 Brookfield CR, Phillips PPJ, Shorten RJ
• Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance.
  The European respiratory journal 2019 Stagg HR, Bothamley GH, Davidson JA, Kunst H, Lalor MK, Lipman MC, Loutet MG, Lozewicz S, Mohiyuddin T, Abbara A, Alexander E, Booth H, Creer DD, Harris RJ, Kon OM, Loebinger MR, McHugh TD, Milburn HJ…
• Proposals on Kaplan-Meier plots in medical research and a survey of stakeholder views: KMunicate.
  BMJ open 2019 Morris TP, Jarvis CI, Cragg W, Phillips PPJ, Choodari-Oskooei B, Sydes MR
• A Shorter Regimen for Rifampin-Resistant Tuberculosis. Reply.
  The New England journal of medicine 2019 Nunn AJ, Phillips PPJ
• Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status.
  BMC pulmonary medicine 2019 Tweed CD, Crook AM, Dawson R, Diacon AH, McHugh TD, Mendel CM, Meredith SK, Mohapi L, Murphy ME, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Gillespie SH
• STREAM: a pragmatic and explanatory trial for MDR-TB treatment.
  The Lancet. Infectious diseases 2019 Abubakar I, Meredith S, Nunn AJ, Phillips PPJ, Rusen ID
• Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility Screening.
  Diagnostics (Basel, Switzerland) 2019 Alipanah N, Shete PB, Nguyen H, Nguyen NV, Luu L, Pham T, Nguyen H, Nguyen P, Tran MC, Pham N, Phan H, Phillips PPJ, Cattamanchi A, Nahid P
• Protein binding of rifampicin is not saturated when using high-dose rifampicin.
  The Journal of antimicrobial chemotherapy 2019 Litjens CHC, Aarnoutse RE, van Ewijk-Beneken Kolmer EWJ, Svensson EM, Colbers A, Burger DM, Boeree MJ, Te Brake LHM, PanACEA-MAMS-TB-01 Team
• Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.
  PLoS medicine 2019 Phillips PPJ, Mitnick CD, Neaton JD, Nahid P, Lienhardt C, Nunn AJ
• A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.
  The New England journal of medicine 2019 Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, van Deun A, Dat PT, Lan N, Master I, Mebrahtu T, Meressa D, Moodliar R, Ngubane N, Sanders K, Squire SB, Torrea G, Tsogt B, Rusen ID…
• Cost minimization analysis of line probe assay for detection of multidrug-resistant tuberculosis in Arkhangelsk region of Russian Federation.
  PloS one 2019 Bogdanova EN, Mariandyshev AO, Balantcev GA, Eliseev PI, Nikishova EI, Gaida AI, Enarson D, Detjen A, Dacombe R, Phillips PPJ, Squire SB, Gospodarevskaya E
• Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.
  Nature medicine 2019 Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM
• A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.
  Nature medicine 2018 Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM
• Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.
  Antimicrobial agents and chemotherapy 2018 Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis…
• Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
  BMC infectious diseases 2018 Tweed CD, Crook AM, Amukoye EI, Dawson R, Diacon AH, Hanekom M, McHugh TD, Mendel CM, Meredith SK, Murphy ME, Murthy SE, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Wills GH, Gillespie SH
• The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018 Svensson EM, Svensson RJ, Te Brake LHM, Boeree MJ, Heinrich N, Konsten S, Churchyard G, Dawson R, Diacon AH, Kibiki GS, Minja LT, Ntingiya NE, Sanne I, Gillespie SH, Hoelscher M, Phillips PPJ, …
• Rethinking non-inferiority: a practical trial design for optimising treatment duration.
  Clinical trials (London, England) 2018 Quartagno M, Walker AS, Carpenter JR, Phillips PP, Parmar MK
• Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis.
  BMC medicine 2018 Murthy SE, Chatterjee F, Crook A, Dawson R, Mendel C, Murphy ME, Murray SR, Nunn AJ, Phillips PPJ, Singh KP, McHugh TD, Gillespie SH, REMoxTB Consortium
• Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
  The Lancet. Respiratory medicine 2018 Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, …
• Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
  BMC medicine 2018 Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, McHugh TD, Mendel C, Meredith S, Mohapi L, Murphy ME, Murray S, Murthy S, Nunn AJ, Phillips PPJ, Singh K, Spigelman M, Gillespie SH
• An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
  Trials 2017 Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, …
• Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis.
  BMC medicine 2017 Murphy ME, Phillips PPJ, Mendel CM, Bongard E, Bateson ALC, Hunt R, Murthy S, Singh KP, Brown M, Crook AM, Nunn AJ, Meredith SK, Lipman M, McHugh TD, Gillespie SH, REMoxTB Consortium
• Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.
  Clinical trials (London, England) 2017 Parmar MK, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown L, Phillips PP, Spears MR, Rowley S, Kaplan R, James ND, Maughan T, Paton N, Royston PJ
• Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil.
  BMC infectious diseases 2017 Ramalho DMP, Miranda PFC, Andrade MK, Brígido T, Dalcolmo MP, Mesquita E, Dias CF, Gambirasio AN, Ueleres Braga J, Detjen A, Phillips PPJ, Langley I, Fujiwara PI, Squire SB, Oliveira MM, Kritski AL, …
• Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial.
  BMC medicine 2017 Witney AA, Bateson AL, Jindani A, Phillips PP, Coleman D, Stoker NG, Butcher PD, McHugh TD, RIFAQUIN Study Team
• Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
  International journal of geriatric psychiatry 2016 Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, Banerjee S, Barber R, Bentham P, Brown RG, Burns A, Dening T, Findlay D, Holmes C, Johnson T, Jones R, Katona C, Lindesay J, Macharouthu A, …
• Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.
  Trials 2016 Bratton DJ, Parmar MK, Phillips PP, Choodari-Oskooei B
• Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.
  The European respiratory journal 2016 Berry C, Yates TA, Seddon JA, Phillips PP, du Cros P, North London TB Journal Club
• The Impact of a Line Probe Assay Based Diagnostic Algorithm on Time to Treatment Initiation and Treatment Outcomes for Multidrug Resistant TB Patients in Arkhangelsk Region, Russia.
  PloS one 2016 Eliseev P, Balantcev G, Nikishova E, Gaida A, Bogdanova E, Enarson D, Ornstein T, Detjen A, Dacombe R, Gospodarevskaya E, Phillips PP, Mann G, Squire SB, Mariandyshev A
• World TB Day 2016: an interview with leading experts in tuberculosis research.
  BMC medicine 2016 Phillips PP, Fletcher HA, Abubakar I, Lipman MC, McHugh TD
• Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2016 Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta …
• Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.
  BMC medicine 2016 Phillips PP, Mendel CM, Burger DA, Crook AM, Nunn AJ, Dawson R, Diacon AH, Gillespie SH
• Challenges in the clinical assessment of novel tuberculosis drugs.
  Advanced drug delivery reviews 2016 Dooley KE, Phillips PP, Nahid P, Hoelscher M
• Infectious Disease Epidemiology. Abubakar I, Stagg HR, Cohen T, Rodrigues LC (Eds.)
  Clinical Trials 2016 Phillips PPJ & Nunn AJ
• DOOR/RADAR: A Gateway Into the Unknown?
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015 Phillips PP, Morris TP, Walker AS
• Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.
  The Lancet. Neurology 2015 Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Sheehan B, Juszczak E, Katona C, Hills R…
• Reducing relapse in tuberculosis treatment.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2015 Nunn AJ, Phillips PP, Abubakar I
• A Step toward an Optimized Rifampin Dose Completed.
  American journal of respiratory and critical care medicine 2015 Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, …
• Comments on 'A modest proposal for dropping poor arms in clinical trials' by Proschan and Dodd.
  Statistics in medicine 2015 Bratton DJ, Choodari-Oskooei B, Phillips PP, Sydes MR, Parmar MK
• A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
  American journal of respiratory and critical care medicine 2015 Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, …
• Safe and effective treatment for patients with isoniazid drug resistance.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2015 Phillips PP, Lipman MC
• Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.
  The New England journal of medicine 2015 Alffenaar JW, Gumbo T, Aarnoutse R
• Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.
  The New England journal of medicine 2015 Sellier PO, Clevenbergh P, Bergmann JF
• Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.
  The Journal of antimicrobial chemotherapy 2015 Heinrich N, Dawson R, du Bois J, Narunsky K, Horwith G, Phipps AJ, Nacy CA, Aarnoutse RE, Boeree MJ, Gillespie SH, Venter A, Henne S, Rachow A, Phillips PP, Hoelscher M, Diacon AH, Pan African …
• Shortening treatment of tuberculosis: lessons from fluoroquinolone trials.
  The Lancet. Infectious diseases 2015 Nimmo C, Lipman M, Phillips PP, McHugh T, Nunn A, Abubakar I
• The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations.
  The Journal of antimicrobial chemotherapy 2014 Bowness R, Boeree MJ, Aarnoutse R, Dawson R, Diacon A, Mangu C, Heinrich N, Ntinginya NE, Kohlenberg A, Mtafya B, Phillips PP, Rachow A, Plemper van Balen G, Gillespie SH
• Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.
  Trials 2014 Nunn AJ, Rusen ID, Van Deun A, Torrea G, Phillips PP, Chiang CY, Squire SB, Madan J, Meredith SK
• Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
  The New England journal of medicine 2014 Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ, REMoxTB Consortium
• Short intensified treatment in children with drug-susceptible tuberculous meningitis.
  The Pediatric infectious disease journal 2014 Turkova A, Seddon JA, Nunn AJ, Gibb DM, Phillips PP
• The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment.
  Journal of clinical microbiology 2014 Honeyborne I, Mtafya B, Phillips PP, Hoelscher M, Ntinginya EN, Kohlenberg A, Rachow A, Rojas-Ponce G, McHugh TD, Heinrich N, Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics
• New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.
  The Lancet. Infectious diseases 2014 Zumla AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, Abubakar I, McHugh TD, Schito M, Maeurer M, Nunn AJ
• A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis.
  BMC medical research methodology 2013 Bratton DJ, Phillips PP, Parmar MK
• Principles for designing future regimens for multidrug-resistant tuberculosis.
  Bulletin of the World Health Organization 2013 Brigden G, Nyang'wa BT, du Cros P, Varaine F, Hughes J, Rich M, Horsburgh CR, Mitnick CD, Nuermberger E, McIlleron H, Phillips PP, Balasegaram M
• Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.
  The Lancet. Respiratory medicine 2013 Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M, …
• An analysis with serious flaws.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013 Nunn AJ, Phillips PP
• Is a 4-month regimen adequate to cure patients with non-cavitary tuberculosis and negative cultures at 2 months?
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2013 Phillips PP, Nunn AJ, Paton NI
• An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.
  PloS one 2013 Phillips PP, Fielding K, Nunn AJ
• Treatment of pulmonary tuberculosis.
  Current opinion in pulmonary medicine 2013 Nunn A, Phillips PP, Abubakar I
• Randomized clinical trials to identify optimal antibiotic treatment duration.
  Trials 2013 Horsburgh CR, Shea KM, Phillips P, Lavalley M
• Reply to Dodd and Proschan.
  The Journal of infectious diseases 2012 Phillips PP, Bratton DJ, Nunn AJ, Hoelscher M
• When inferiority meets non-inferiority: implications for interim analyses.
  Clinical trials (London, England) 2012 Bratton DJ, Williams HC, Kahan BC, Phillips PP, Nunn AJ
• Innovative trial designs are practical solutions for improving the treatment of tuberculosis.
  The Journal of infectious diseases 2012 Phillips PP, Gillespie SH, Boeree M, Heinrich N, Aarnoutse R, McHugh T, Pletschette M, Lienhardt C, Hafner R, Mgone C, Zumla A, Nunn AJ, Hoelscher M
• Donepezil and memantine for moderate-to-severe Alzheimer's disease.
  The New England journal of medicine 2012 Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan …
• CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.
  American journal of respiratory and critical care medicine 2011 Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, …
• Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment.
  Journal of clinical microbiology 2011 Honeyborne I, McHugh TD, Phillips PP, Bannoo S, Bateson A, Carroll N, Perrin FM, Ronacher K, Wright L, van Helden PD, Walzl G, Gillespie SH
• Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2010 Perrin FM, Woodward N, Phillips PP, McHugh TD, Nunn AJ, Lipman MC, Gillespie SH
• Determining the minimum clinically important differences for outcomes in the DOMINO trial.
  International journal of geriatric psychiatry 2010 Howard R, Phillips P, Johnson T, O'Brien J, Sheehan B, Lindesay J, Bentham P, Burns A, Ballard C, Holmes C, McKeith I, Barber R, Dening T, Ritchie C, Jones R, Baldwin A, Passmore P, Findlay D, Hughes …
• Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells.
  Tuberculosis (Edinburgh, Scotland) 2010 Dhillon J, Andries K, Phillips PP, Mitchison DA
• Challenges of Phase III study design for trials of new drug regimens for the treatment of TB.
  Future medicinal chemistry 2010 Phillips PP, Nunn AJ
• Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia.
  Antimicrobial agents and chemotherapy 2010 Mwenya DM, Charalambous BM, Phillips PP, Mwansa JC, Batt SL, Nunn AJ, Walker S, Gibb DM, Gillespie SH
• Biomarkers for tuberculosis disease activity, cure, and relapse.
  The Lancet. Infectious diseases 2010 Phillips PP, Davies GR, Mitchison DA
• Timing of relapse in short-course chemotherapy trials for tuberculosis.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2010 Nunn AJ, Phillips PP, Mitchison DA
• DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.
  Trials 2009 Jones R, Sheehan B, Phillips P, Juszczak E, Adams J, Baldwin A, Ballard C, Banerjee S, Barber B, Bentham P, Brown R, Burns A, Dening T, Findlay D, Gray R, Griffin M, Holmes C, Hughes A, Jacoby R, …
• Design issues in pivotal drug trials for drug sensitive tuberculosis (TB).
  Tuberculosis (Edinburgh, Scotland) 2008 Nunn AJ, Phillips PP, Gillespie SH
• Biomarkers and surrogate end points in clinical trials of tuberculosis treatment.
  The Journal of infectious diseases 2007 Davies GR, Phillips PP, Nunn AJ
• Cannabis in postoperative pain: a pharmacokinetic study
  British Journal of Anaesthesia 2004 A. Holdcroft, C. Dore, P. Phillips, M. Maze and M. Hanna